Physician profile
Sarah A Rust
NPI 1366977423
$1,277.64
in general payments reported to CMS, 2019-2025
26 companies · $168 in 2025
The $168 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $54.19 · 2021: $250 · 2022: $366 · 2023: $238 · 2024: $201 · 2025: $168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $608.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $607.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $173.42 | 2021-2024 | Verquvo, Vaxelis, Gardasil 9 |
| Tris Pharma INC | $150.96 | 2020-2024 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $150.87 | 2020-2023 | Trintellix |
| Glaxosmithkline, LLC. | $121.48 | 2022-2025 | Shingrix, Arexvy |
| Novo Nordisk INC | $108.07 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $84.65 | 2025 | Dupixent |
| Ironshore Pharmaceuticals INC. | $63.64 | 2022-2024 | Jornay Pm |
| Abiomed | $53.52 | 2024 | Impella |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $42.89 | 2025 | Caplyta |
| Abbvie INC. | $35.41 | 2022-2024 | |
| Supernus Pharmaceuticals, INC. | $33.35 | 2021-2023 | Qelbree |
| Ultragenyx Pharmaceutical INC. | $28.90 | 2022 | |
| Corium, LLC | $27.33 | 2023 | Azstarys |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.47 | 2024 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $19.92 | 2023 | Nuedexta |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $19.86 | 2025 | Repatha, Otezla |
| Sanofi Pasteur INC. | $17.77 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $16.86 | 2022 | |
| Upsher-Smith Laboratories LLC | $16.17 | 2021 | |
| Avanir Pharmaceuticals, INC. | $14.90 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.31 | 2024 | Zoryve |
| Amarin Pharma, INC. | $14.12 | 2020 | |
| Currax Pharmaceuticals LLC | $13.46 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $12.58 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.30 | 2021 | |
| Organon LLC | $10.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Rust listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.